Korro Bio, Inc. (KRRO) — 10-Q Filings

10-Q Filings (7)

• 10-Q Filing — May 7, 2026
• Korro Bio's Cash Dwindles Amidst Program Pivot and Novo Nordisk Pause — Nov 12, 2025 Risk: high
  Korro Bio, Inc. reported a net loss of $18.061 million for the three months ended September 30, 2025, a decrease from the $20.999 million net loss in the same p
• Korro Bio's Q2 Net Loss Widens to $28.3M Amid R&D Re-prioritization — Aug 12, 2025 Risk: high
  Korro Bio, Inc. reported a net loss of $28.3 million for the three months ended June 30, 2025, an increase from a net loss of $25.7 million for the same period
• Korro Bio Files Q1 2025 10-Q — May 7, 2025 Risk: medium
  Korro Bio, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Frequency Therapeutics, Inc., reported on its financial posi
• Korro Bio Files 10-Q: Updates on Operations and Novo Nordisk Deal — Nov 12, 2024 Risk: medium
  Korro Bio, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results and provided updates on its business operations.
• Korro Bio Files Q2 2024 10-Q — Aug 13, 2024 Risk: medium
  Korro Bio, Inc. filed its 10-Q for the period ending June 30, 2024, reporting on its financial performance and business operations. The company, formerly known
• Korro Bio, Inc. Files 10-Q for Period Ending March 31, 2024 — May 14, 2024 Risk: low
  Korro Bio, Inc. (KRRO) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Korro Bio, Inc. (KRRO) filed a 10-Q report for the period ending March 31,

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX